PTN Palatin Technologies Inc.

0.79
-0.02  -3%
Previous Close 0.81
Open 0.81
Price To Book 1.88
Market Cap 181,276,661
Shares 229,116,104
Volume 806,882
Short Ratio 27.14
Av. Daily Volume 917,211
Stock charts supplied by TradingView

NewsSee all news

  1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update

    CRANBURY, N.J., Nov. 13, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the

  2. Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019

    CRANBURY, N.J., Nov. 7, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its first quarter fiscal year 2020 operating results on Wednesday, November 13, 2019 before the open of the U.S. financial

  3. Thinking about buying stock in Canopy Growth, Micron Technology, Palatin Technologies, SINTX Technologies, or Tilray?

    NEW YORK, Sept. 12, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, MU, PTN, SINT, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results

    CRANBURY, N.J., Sept. 12, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the

  5. Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019

    CRANBURY, N.J., Sept. 11, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 before the open of the U.S.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced June 21, 2019.
Vyleesi (Bremelanotide)
Female sexual dysfunction (FSD)
Phase 2 trial to commence 4Q 2019.
PL-3994
Heart failure
Phase 2 trial to commence 1Q 2020.
PL-8177
Non-infectious uveitis
Phase 2 trial to commence 2Q 2020 with data due 1H 2021.
PL-8177
Ulcerative colitis

Latest News

  1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update

    CRANBURY, N.J., Nov. 13, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the

  2. Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019

    CRANBURY, N.J., Nov. 7, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its first quarter fiscal year 2020 operating results on Wednesday, November 13, 2019 before the open of the U.S. financial

  3. Thinking about buying stock in Canopy Growth, Micron Technology, Palatin Technologies, SINTX Technologies, or Tilray?

    NEW YORK, Sept. 12, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, MU, PTN, SINT, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results

    CRANBURY, N.J., Sept. 12, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the

  5. Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019

    CRANBURY, N.J., Sept. 11, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 before the open of the U.S.